Literature DB >> 24815347

Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.

M Zucker1, U Seligsohn, O Salomon, A S Wolberg.   

Abstract

BACKGROUND: Factor XI (FXI) deficiency is a rare autosomal recessive disorder. Many patients with even very low FXI levels (< 20 IU dL(-1) ) are asymptomatic or exhibit only mild bleeding, whereas others experience severe bleeding, usually following trauma. Neither FXI antigen nor activity predicts the risk of bleeding in FXI-deficient patients.
OBJECTIVES: (i) Characterize the formation, structure and stability of plasma clots from patients with severe FXI deficiency and (ii) determine whether these assays can distinguish asymptomatic patients ('non-bleeders') from those with a history of bleeding ('bleeders').
METHODS: Platelet-poor plasmas were prepared from 16 severe FXI-deficient patients who were divided into bleeders or non-bleeders, based on bleeding associated with at least two tooth extractions without prophylaxis. Clot formation was triggered by recalcification and addition of tissue factor and phospholipids in the absence or presence of tissue plasminogen activator and/or thrombomodulin. Clot formation and fibrinolysis were measured by turbidity and fibrin network structure by laser scanning confocal microscopy.
RESULTS: Non-bleeders and bleeders had similarly low FXI levels, normal prothrombin times, normal levels of fibrinogen, factor VIII, von Willebrand factor and factor XIII, and normal platelet number and function. Compared with non-bleeders, bleeders exhibited lower fibrin network density and lower clot stability in the presence of tissue plasminogen activator. In the presence of thrombomodulin, seven of eight bleeders failed to form a clot, whereas only three of eight non-bleeders did not clot.
CONCLUSIONS: Plasma clot structure and stability assays distinguished non-bleeders from bleeders. These assays may reveal hemostatic mechanisms in FXI-deficient patients and have clinical utility for assessing the risk of bleeding.
© 2014 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding; factor XI; factor XI deficiency; fibrin clot lysis time; plasma clot lysis time

Mesh:

Substances:

Year:  2014        PMID: 24815347      PMCID: PMC4107079          DOI: 10.1111/jth.12600

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  35 in total

1.  Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity.

Authors:  F Peyvandi; D Di Michele; P H B Bolton-Maggs; C A Lee; A Tripodi; A Srivastava
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

2.  Native fibrin gel networks observed by 3D microscopy, permeation and turbidity.

Authors:  B Blombäck; K Carlsson; B Hessel; A Liljeborg; R Procyk; N Aslund
Journal:  Biochim Biophys Acta       Date:  1989-07-27

3.  Factor XI deficiency in Ashkenazi Jews in Israel.

Authors:  R Asakai; D W Chung; E W Davie; U Seligsohn
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

4.  Inheritance and bleeding in factor XI deficiency.

Authors:  P H Bolton-Maggs; B Young Wan-Yin; A H McCraw; J Slack; P B Kernoff
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

5.  High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews.

Authors:  U Seligsohn
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

6.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Authors:  P A Von dem Borne; L Bajzar; J C Meijers; M E Nesheim; B N Bouma
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

7.  Blood coagulation in hemophilia A and hemophilia C.

Authors:  K M Cawthern; C van 't Veer; J B Lock; M E DiLorenzo; R F Branda; K G Mann
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

8.  Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.

Authors:  P A von dem Borne; J C Meijers; B N Bouma
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  Dental surgery in patients with severe factor XI deficiency without plasma replacement.

Authors:  S Berliner; I Horowitz; U Martinowitz; B Brenner; U Seligsohn
Journal:  Blood Coagul Fibrinolysis       Date:  1992-08       Impact factor: 1.276

10.  Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Authors:  L Bajzar; R Manuel; M E Nesheim
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  25 in total

Review 1.  Clot Structure and Implications for Bleeding and Thrombosis.

Authors:  Emily Mihalko; Ashley C Brown
Journal:  Semin Thromb Hemost       Date:  2019-10-15       Impact factor: 4.180

Review 2.  Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.

Authors:  P James; O Salomon; D Mikovic; F Peyvandi
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

Review 3.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

4.  Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.

Authors:  Cristina Puy; Erik I Tucker; Anton Matafonov; Qiufang Cheng; Keith D Zientek; Dave Gailani; András Gruber; Owen J T McCarty
Journal:  Blood       Date:  2015-01-13       Impact factor: 22.113

5.  Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.

Authors:  Steven P Grover; Clare M Schmedes; Alyson C Auriemma; Emily Butler; Molly L Parrish; Adam Miszta; Audrey C Cleuren; Mayken Visser; Stefan Heitmeier; Jens J Posma; Henri M Spronk; Silvio Antoniak; Alisa S Wolberg; Rafal Pawlinski; David Gailani; Nigel Mackman
Journal:  Blood Adv       Date:  2020-01-14

6.  The clinical management of factor XI deficiency in pregnant women.

Authors:  Allison P Wheeler; Celeste Hemingway; David Gailani
Journal:  Expert Rev Hematol       Date:  2020-06-12       Impact factor: 2.929

Review 7.  Fibrinogen and Fibrin in Hemostasis and Thrombosis.

Authors:  Sravya Kattula; James R Byrnes; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03       Impact factor: 8.311

Review 8.  The hemostatic role of factor XI.

Authors:  Cristina Puy; Rachel A Rigg; Owen J T McCarty
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

9.  Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

Authors:  Gillian N Gidley; Lori A Holle; John Burthem; Paula H B Bolton-Maggs; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-05-22

10.  Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Authors:  Oliver Königsbrügge; Günter Weigel; Peter Quehenberger; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2018-02-07       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.